COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT

Therapeutic methods and pharmaceutical compositions for treating a cancer, including a B cell hematological malignancy selected from the group consisting of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), non-Hodgkin's lymphoma (NHL), diffuse large B cell lymphoma (DLBCL),...

Full description

Saved in:
Bibliographic Details
Main Author ROTHBAUM, Wayne
Format Patent
LanguageEnglish
French
Published 20.05.2021
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Therapeutic methods and pharmaceutical compositions for treating a cancer, including a B cell hematological malignancy selected from the group consisting of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), non-Hodgkin's lymphoma (NHL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Hodgkin's lymphoma, B cell acute lymphoblastic leukemia (B-ALL), Burkitt's lymphoma, and Waldenström's macroglobulinemia (WM). L'invention concerne également des méthodes thérapeutiques et des compositions pharmaceutiques pour le traitement du cancer, comprenant une malignité hématologique des lymphocytes B choisie dans le groupe constitué par la leucémie lymphoïde chronique (CLL), la leucémie à petits lymphocytes (SLL), le lymphome non hodgkinien (NHL), le lymphome diffus à grandes cellules B (DLBCL), le lymphome folliculaire (FL), le lymphome à cellules du manteau (MCL), le lymphome de Hodgkin, la leucémie lymphoblastique aiguë des lymphocytes B (B-ALL), le lymphome de Burkitt et la macroglobulinémie de Waldenstrôm (WM).
Bibliography:Application Number: WO2020US60422